Chinese biotech Bio Thera Solutions (688177 SH) has filed a new drug application (NDA) with China’s National Medical Products Administration (NMPA) to gain approval of what would be the country's first biosimilar of Actemra (tocilizumab).
The biosimilar was in-licensed from US biotech Biogen (Nasdaq: BIIB) in April. Originated by Swiss pharma giant Roche (ROG: SIX), Actemra was approved in China in 2016 to treat rheumatoid arthritis and other diseases, such as systemic juvenile idiopathic arthritis.
Global sales Actemra/RoActemra rose 30% year-on-year to 2.69 billion Swiss francs ($2.95 billion) for the first nine months of the current year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze